Nirsevimab
Nirsevimab Basic information
- Product Name:
- Nirsevimab
- Synonyms:
-
- Nirsevimab
- Research Grade Nirsevimab (DVV02802)
- MEDI8897
- Research Grade Nirsevimab
- CAS:
- 1989556-22-0
- MW:
- 0
- Mol File:
- Mol File
Nirsevimab Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Nirsevimab Usage And Synthesis
Uses
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections[1][2].
in vivo
Nirsevimab (10-10000 μg/kg; i.m.) inhibits the antibody response in the respiratory mucosa of mice when pre-administered prior to RSV virus infection[2].
| Animal Model: | 3-week-old female BALB/c mice[2]. |
| Dosage: | 10 μg/kg, 100 μg/kg, 1 mg/kg, 10 mg/kg |
| Administration: | Intramuscular injection (i.m.); administer medication 24 hours prior to RSV virus exposure |
| Result: | Inhibited the secretion of sIgA, mucosal IgA, and mucosal IgG in the offspring subsequent to the initial RSV infection. |
References
[1] Brady T, et al. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. Front Immunol. 2023 Oct 11;14:1283120. DOI:10.3389/fimmu.2023.1283120
[2] Ma J, et. Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure. Front Immunol. 2024 Apr 30;15:1377374. DOI:10.3389/fimmu.2024.1377374
NirsevimabSupplier
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com